Sun Pharma deal
A deal has been signed between India's leading pharmaceutical company Sun Pharma and Organon. The company is a subsidiary of New York-listed healthcare firm Organon & Co. Is engaged in raising funding to repay about 12 billion dollars, approximately Rs 1 lakh crore. For this mega deal, Sun Pharma can use a mix of debt, bonds and its cash reserves instead of traditional funding, adopting an all-pocket strategy.
According to the ET report, Sun Pharma is considering adopting all pocket formula to finance this deal. This means that the company will use multiple funding options simultaneously, which will include foreign debt, bond issues and its cash reserves. The company may also negotiate with the existing bondholders of Organon, so that their holdings can be converted into new debt of Sun Pharma.
This is also the plan
According to media reports, the company is also working on a plan to issue euro-denominated bonds. The potential credit rating of this bond may be better than the current rating of Organon, which will help in attracting investors. Apart from this, Sun Pharma is planning to raise 3 to 4 billion dollars through foreign debt.
Citi India CEO K. According to Balasubramaniam, the bank has underwritten this acquisition and will work with Sun Pharma on its financial structuring in the coming months. This will also include finalizing the long-term capital structure. Sun Pharma has already indicated that it will use $2 to $2.5 billion from its cash reserves for this deal. In this way, the company wants to protect its credit profile by balancing debt and internal resources.
-
IPL 2026: Why Vaibhav Sooryavanshi was called 'unprofessional'? Jitesh Sharma reveals truth
-
Exciting Job Openings at Coal India for Engineering Graduates
-
Union Bank of India Apprenticeship Recruitment: Apply Before May 19, 2026
-
Rajasthan Staff Selection Board Announces 3,540 Teaching Associate Vacancies
-
Coal India Management Trainee Recruitment: Apply Soon for 660 Positions
